Our Oligo Splicing and Chemical Modification Services support research teams that need splice-switching oligonucleotides (SSOs) and other steric-blocking antisense constructs designed, modified, synthesized, and characterized for pre-mRNA splicing studies. These projects require more than standard oligo production. Sequence placement must match splice sites or regulatory motifs, the chemistry must support a non-cleaving splice-modulation mechanism, and the final construct must remain workable in downstream screening, cell-based studies, and isoform analysis workflows.
We integrate target-region review, splice-switching oligo design, custom chemistry selection, synthesis, purification, and analytical confirmation into one coordinated service flow. Whether your team is evaluating exon skipping, exon inclusion, splice correction, or broader isoform engineering strategies, we help translate project goals into fit-for-purpose modified oligos with practical attention to manufacturability, sequence-dependent risk, and decision-ready data packages. Our broader antisense oligonucleotide synthesis and oligo modification capabilities also support follow-on optimization when a splice-modulating program expands.
Finding a Productive Binding Site: Strong complementarity alone does not guarantee a splice shift. Effective SSO design must account for exon-intron architecture, splice donor or acceptor context, enhancer or silencer motifs, and local RNA accessibility so that the oligo binds where it can actually redirect the splicing outcome.
Choosing Non-Cleaving Chemistry: Splice-switching programs usually rely on steric blocking rather than transcript cleavage. We help teams distinguish splice-modulating designs from gapmer-style RNase H strategies and select appropriate backbone and sugar modifications, including options related to oligo backbone modification and 2'-modifications.
Balancing Affinity, Specificity, and Solubility: Higher-affinity chemistries can improve target engagement, but over-dense modification patterns may complicate specificity, purification, or handling. We review positional chemistry, oligo length, GC burden, and sequence motifs to reduce avoidable design risk before synthesis begins.
Managing Heavily Modified Synthesis: PMO, LNA/BNA-containing sequences, chimeric backbones, and conjugated constructs can introduce process complexity, impurity resolution challenges, and different analytical requirements. We build practical synthesis and purification plans around the actual chemistry rather than treating all modified oligos as interchangeable.
Generating Actionable Readouts: Discovery teams need more than a shipment of oligos. We structure projects to support identity confirmation, purity review, documentation, and optional analytical or screening-oriented follow-up so that candidate ranking and redesign decisions can be made with confidence.
Our service scope is built for biotech, pharmaceutical, academic, and CRO teams working on splice-switching oligonucleotide discovery, modified antisense screening, and chemistry-enabled isoform modulation studies. We support projects from early target assessment through custom synthesis, analytical review, and optimization planning.
Instead of offering a single generic modified oligo workflow, we organize support around the real technical decisions that determine whether a splice-modulating oligo program moves forward efficiently.
Different splice-modulating projects benefit from different chemical architectures. The table below is designed to help research teams compare common modification options in terms of mechanism fit, practical benefits, and development cautions before sequence finalization.
| Chemistry Format | Key Structural Feature | Why Teams Choose It | Main Design Cautions | Typical Project Fit |
| 2'-OMe PS | 2'-O-methyl ribose with phosphorothioate backbone | Practical balance of nuclease resistance, manufacturability, and steric-blocking utility for discovery screens | Full PS content can lower duplex Tm and increase non-specific protein interactions, so placement and length still matter | Early splice-switching screens, exon-walking panels, and chemistry benchmarking |
| 2'-MOE PS | 2'-methoxyethyl sugar modification paired with phosphorothioate linkages | Stronger affinity and high stability in fully modified steric-blocking designs | Bulkier sugar chemistry can change positional tolerance and may require tighter sequence optimization | Mature splice-modulation candidates and higher-stability research constructs |
| LNA/BNA Mixmer | Locked or bridged ribose residues placed within a mixed oligo sequence | High affinity enables shorter designs and helps with difficult or partially inaccessible targets | Overuse can narrow the optimization window by affecting specificity, solubility, or purification behavior | Short target windows, high-affinity rescue designs, and targeted positional screening |
| PMO | Morpholine ring and charge-neutral phosphorodiamidate backbone | Highly nuclease-resistant, non-cleaving steric-blocking format for splice modulation | Requires chemistry-specific synthesis, purification, and delivery planning rather than standard oligo assumptions | Exon skipping or inclusion studies where a neutral-backbone format is preferred |
| Chimeric Designs | Region-specific combination of sugar and backbone modifications within one sequence | Fine-tunes affinity, stability, and manufacturability without relying on a single uniform chemistry | Positional zoning increases design and analytical complexity, so documentation and QC strategy become more important | Lead optimization, comparative chemistry studies, and customer-defined design hypotheses |
Successful projects depend on early control of sequence logic, chemistry zoning, manufacturability, and analytical expectations. This matrix shows the major review categories we use to de-risk splice-switching oligo programs before and after synthesis.
| Review Category | What We Evaluate | Why It Matters | Typical Output | Project Stage |
| Target Region Assessment | Exon or intron boundaries, splice motifs, enhancer or silencer overlap, transcript isoforms, and local accessibility | Prevents wasted synthesis on target windows that are complementary but not splice-productive | Ranked design regions and targeting rationale | Discovery |
| Sequence Architecture Planning | Oligo length, mismatch sensitivity, GC distribution, motif avoidance, and control sequence design | Aligns binding behavior with the desired splice outcome and screening strategy | Candidate sequences or panel layout | Discovery |
| Chemistry Zoning | Uniform versus mixed modification patterns, backbone choice, terminal design, and regional chemistry placement | Balances affinity, steric-blocking performance, and synthesis practicality | Modification map and chemistry recommendation | Discovery / Optimization |
| Synthesis Feasibility | Sequence-dependent synthesis burden, impurity risk, deprotection sensitivity, and purification difficulty | Helps control timelines, yields, and scale decisions for heavily modified constructs | Fit-for-purpose synthesis and purification plan | Pre-synthesis |
| Analytical Strategy | Identity confirmation, purity targets, method suitability, and chemistry-specific QC requirements | Ensures the final deliverable can be interpreted correctly across different modification classes | QC package and release criteria proposal | Pre- and Post-synthesis |
| Conjugation Planning | Labeling need, linker placement, payload compatibility, and impact on splice-target binding | Prevents loss of activity when a construct must also support tracking, capture, or uptake studies | Conjugate design recommendation | Design / Optimization |
| Screening Design | Candidate counts, control sets, chemistry comparisons, and primary splice readout strategy | Improves the quality of the first experimental round and simplifies candidate triage | Screening plan inputs and comparison framework | Optimization |
| Redesign Review | Weak splice shift, inconsistent isoform response, assay mismatch, or chemistry-limited performance | Converts first-pass data into focused redesign rather than broad trial-and-error iteration | Revised sequence or chemistry options | Optimization |
Our workflow is designed for research-stage splice-switching programs that need disciplined handoff from target selection to modified oligo delivery, analytical review, and next-step optimization planning.
We start by defining the transcript target, desired splice outcome, sequence constraints, preferred oligo format, and required deliverables. This step ensures the project is framed around exon skipping, exon inclusion, splice blocking, or isoform control rather than a generic antisense request.
Our team reviews splice-relevant motifs, accessibility considerations, oligo length options, and feasible modification classes. We then propose the most appropriate chemistry path based on mechanism, sequence behavior, and manufacturing practicality.
Candidate sequences are finalized as single leads or comparative panels. Control oligos, mismatch references, terminal functions, and positional chemistry layouts are defined before synthesis so the screening plan stays aligned with the technical question being tested.
We execute synthesis and purification using methods matched to the chosen chemistry platform. Heavily modified, neutral-backbone, or conjugated constructs are handled with chemistry-aware process logic to support consistent material quality.
Identity, purity, and project-specific analytical outputs are compiled into a structured data package. When needed, we align the reporting format with customer screening workflows, procurement expectations, and downstream technical review requirements.
Material and documentation are delivered with support for follow-on questions, redesign planning, and next-round candidate expansion. This helps teams convert first-pass experimental data into a more focused second design cycle instead of restarting from scratch.
Splice-switching programs are especially sensitive to design logic, chemistry choice, and analytical discipline. Our service platform is structured to help customers make these decisions earlier and with fewer avoidable handoff gaps between sequence concept, chemical execution, and experimental use.
Our oligo splicing and chemical modification services are suited to research and development settings where teams need to redirect pre-mRNA splicing, compare isoform outcomes, and optimize chemically modified oligos for reliable experimental performance.
If your program requires splice-switching oligo design, custom chemical modification, PMO or LNA-enabled builds, conjugation support, or analytical review for steric-blocking antisense constructs, our team can help you move from target concept to usable research material with a more structured workflow. We work with biotech companies, pharmaceutical discovery groups, CROs, and academic researchers to define splice goals, select practical chemistries, synthesize project-specific oligos, and support data-driven optimization. Contact us to discuss your oligo splicing and chemical modification requirements.
Splicing is the process of editing pre-messenger RNA (pre-mRNA) by removing introns and joining exons, creating mature mRNA that serves as a template for protein synthesis. This is crucial for regulating gene expression and protein production.
SSOs are modified antisense oligonucleotides that bind to pre-mRNA, disrupting normal splicing by blocking RNA-RNA interactions. This allows for the targeted modulation of gene expression, providing a tool for therapeutic applications.
PMOs replace the sugar ring with a morpholine ring and use a neutral backbone, which reduces plasma protein binding. This modification improves tolerance and splicing efficiency in vivo.
2'-OMePS replaces the 2'-hydroxyl group with a 2'-O-2-methoxyethyl group, making the oligonucleotide more stable. It also protects against nuclease degradation while maintaining base-pairing functionality.
LNA and AmNA modifications enhance oligonucleotide binding to complementary RNA, improving splicing efficiency. These modifications are particularly useful in exon skipping and splicing regulation.
GuNA-modified SSOs enhance exon skipping and improve splicing regulation by promoting efficient binding. This modification is ideal for controlling gene expression.
We offer purification methods including desalting, PAGE, and HPLC to ensure high purity. These methods guarantee reliable and consistent results for your research.
Loading ......
